NCT02356250 is a clinical trial in Portal Hypertension, sponsored by Eyal Ashkenazi.

Who is sponsoring NCT02356250?

NCT02356250 is sponsored by Eyal Ashkenazi.

What condition does NCT02356250 study?

NCT02356250 studies Portal Hypertension, Cirrhosis.

Is NCT02356250 still recruiting?

NCT02356250 is currently withdrawn. Last updated 26 July 2018.

Last reviewed 2018-07-26 · How we verify

NCT02356250

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Pilot Study: Defining Peripheral Endothelial Function in Portal Hypertensive Cirrhotic Patients

Withdrawn Last updated 26 July 2018

What this trial tests

trial in Portal Hypertension. Withdrawn.

Timeline

18 February 2015

Primary endpoint
29 November 2016

29 November 2016

Quick facts

Lead sponsor	Eyal Ashkenazi
Status	Withdrawn
Study type	OBSERVATIONAL
Start date	18 February 2015
Primary completion	29 November 2016
Estimated completion	29 November 2016

Conditions studied

Portal Hypertension — all drugs for Portal Hypertension →
Cirrhosis — all drugs for Cirrhosis →

Sponsor

Eyal Ashkenazi

Who can join

Adults 18 to 75, any sex, with Portal Hypertension or Cirrhosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Rationale for the study: To try and define PEF in cirrhotic patients with CSPH, and maybe to try to find a correlation between HVPG ( hepatic vein pressure gradient ) result and PEF result in a way that the result of the PEF test will be able to predict if a patient has CSPH (yes of no). By this, to try and develop a portable office-based device that can produce immediate results in a non-invasive manner in cirrhotic patients and help in evaluating prognosis in these patients in a noninvasive manner. Aim: The aim of this study is to try and characterize the peripheral endothelial function (PEF) in patient with cirrhosis and CSPH. This will be evaluated by measuring the PEF in every patient before evaluating his HVPG level in a hemodynamic study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Portal Hypertension

Currently open trials in the same condition.

NCT07439939 — Exploration of Systemic and Portal Hemostasis in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Place · recruiting
NCT07521332 — Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis · Phase 4 · recruiting
NCT07419724 — Construction of a Portal Hypertension Biobank · recruiting
NCT07116096 — Effect of Handgrip Strength on Portal Vein Hemodynamics in Patients With Liver Cirrhosis · NA · recruiting
NCT07080697 — A Study to Evaluate Splenectomy on Debridement for Acute Necrotizing Pancreatitis With Pancreatic Sinistral Portal Hyper · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02356250 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eyal Ashkenazi
Last refreshed: 26 July 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02356250.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing